Stem Cell Culture Metabolite Control Patents: Leaders & Trends 2026
- 62.5% of the 64 records in scope sit with just five assignees, with the leader alone holding 14 records.
- Filings grew from 1 in 2021 to 3 in 2024 a +200% rise over that span, even as 2025-2026 counts are still filling in due to publication lag.
- C12M bioreactor and apparatus claims cover 32.8% of records yet sit well behind C12N's 90.6%, pointing to open apparatus-side claim space.
Filing growth compares 2021 (1 records) with 2024 (3) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 64 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks 64 published patent records combining stem, pluripotent or progenitor cell culture with explicit metabolite control language — lactate control, ammonia control, glucose or glutamine uptake, pH regulation, or redox state — filed against the core cell-culture IPC classes C12N5/074, C12N5/0735 and C12M3/00. It is a narrow, method-and-apparatus-focused slice of the broader stem cell field, built around records that make an explicit claim to controlling a culture-medium metabolite rather than simply describing a culture protocol.
The scope runs from 2015 through the 2026-07-31 cut-off, giving roughly a decade of filing behaviour to compare leaders, technology mix and receiving-office patterns against.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 64 records: how filing activity has moved year over year, and which technology classes those filings actually claim against.
Filing trend: a small but growing field
Filings peaked at 5 in 2019 and dipped afterward before recovering: 2021 held at 1 and climbed to 3 by 2024, a +200% increase over that three-year span. 2025 and 2026 show fewer records only because publication lags filing by roughly 18 months — those years are not yet complete and should not be read as a slowdown.
Technology composition: apparatus claims trail biology claims
C12N (microorganisms and genetic engineering) touches 90.6% of the 64 records, confirming that most filings are anchored in cell-biology method claims. C12M (bioreactors and enzyme apparatus) reaches only 32.8%, and C12Q (enzyme/DNA measurement) just 9.4% — the apparatus and real-time-monitoring side of metabolite control is comparatively thin against the biology side, even though metabolite control is inherently a measurement-and-apparatus problem as much as a biological one.
Shares are the percentage of the 64 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Stem Cell Culture Metabolite Control with Eureka
This page is one run against one query. Ask Eureka your own question about stem cell culture metabolite control and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
EP2825638A1 — Generation of brown adipose tissue from mesenchymal cells
Methods of generating functional human brown adipocytes by exposing human stem cells, progenitor cells, or white adipocytes to a differentiation cocktail comprising one or more browning agents, such as macromolecular crowders, and optionally adipogenic agents. The filing also covers the resulting brown adipocyte populations, their use, and methods of administering a pharmaceutical composition containing the differentiation cocktail to an individual.Filed by National University of Singapore, published 2015-01-21.
View filing details| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO1992011355A1 | Method for culturing and transforming human stem cell-containing compositions | 105 |
| 2 | WO2015131143A1 | Materials and methods for expansion of stem cells | 31 |
| 3 | CN102015998A | 微流体成像细胞分析 | 24 |
| 4 | WO2013137826A1 | Generation of brown adipose tissue (BAT) from mesenchymal cells | 19 |
| 5 | US20180282699A1 | Microenvironments for self-assembly of islet organoids from stem cells differentiation | 15 |
| 6 | US20150110749A1 | Generating pluripotent cells de novo | 15 |
| 7 | WO2009100028A1 | Microfluidic imaging cytometry | 8 |
| 8 | US8178349B2 | Homogeneous neural precursor cells | 6 |
| 9 | US20190161738A1 | Combinational use of mechanical manipulation and programin to generate pluripotent stem cells from somatic ce… | 4 |
| 10 | EP1473360A2 | Methods for the ex-vivo replication and stable genetic transformation of human stem cells | 4 |
Citation counts reflect influence within this searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three findings that shape where a new filing would land relative to existing claims.
Filing rights sit with a small group
Five assignees hold 62.5% of the 64 records in scope, and the top 10 combined reach 93.8%. A new entrant is negotiating claim space that is already dense at the top, though the long tail beyond the top 10 is thin — most of the 30 ranked companies hold only one or two records each.
Growth is real but recent years understate it
Filings rose from 1 in 2021 to 3 in 2024, a +200% increase over three years, after peaking earlier at 5 in 2019. 2025 and 2026 counts look low only because of the roughly 18-month publication lag, not because interest has cooled.
Apparatus-side claims lag biology claims
C12M bioreactor and apparatus classifications appear in 32.8% of records against C12N's 90.6%, and C12Q measurement classifications sit at just 9.4%. Real-time monitoring and control hardware for lactate, ammonia or pH is comparatively under-claimed relative to the biological methods it supports.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to stem cell culture metabolite control, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranking covers 30 companies total, counted by patent family. It is concentrated at the top, and momentum across the leaders has flattened in the most recent complete year.
One clear leader, then a steep drop
The top-ranked assignee holds 14 of the 64 records, roughly three and a half times the fifth-place count of 4. The gap between first place and the rest of the top five is the sharpest structural feature of this ranking.
A flat plateau from fifth to tenth
Fifth place and tenth place both hold 4 records, meaning the assignees ranked 5 through 10 are filing at comparable, modest volumes rather than showing a steep tail-off. Together the top 10 account for 93.8% of all records.
Leaders show no new records in the latest year
Every leading assignee tracked for recent-year momentum, including one showing a -100% year-over-year change, recorded zero filings in the latest year. Given the roughly 18-month publication lag, this reads as a reporting gap rather than a genuine stop in activity.
| Assignee | Recent year | YoY |
|---|---|---|
| The Regents of the University of Michigan | 0 | — |
| VCell Therapeutics Inc. | 0 | — |
| Wayne State University | 0 | -100% |
| The Chinese University of Hong Kong | 0 | — |
| National Center for Global Health and Medicine (Japan) | 0 | — |
| ID Pharma Co., Ltd. | 0 | — |
| National University of Singapore | 0 | — |
| Auckland UniServices Limited | 0 | — |
Where to take this analysis
The dataset points to a field with a concentrated top and a thin apparatus layer. These are the natural next steps.
Map the apparatus white space in detail
C12M and C12Q classes are comparatively light against C12N. Running a focused search on real-time metabolite sensing and closed-loop feedback claims would clarify how open that space really is before committing to a filing direction.
Explore apparatus claims in Eureka →Watch the mid-tier cluster
The flat plateau from fifth to tenth place suggests several assignees are filing at similar rates without a clear breakout leader. Tracking their next filings could reveal which direction the field consolidates toward.
Track assignee activity in Eureka →Revisit growth once 2025-2026 data settles
Because publication lag understates the most recent two years, the +200% growth figure through 2024 is the most reliable read for now. Re-check the trend once later filings publish.
Set a filing alert in Eureka →Common questions on this landscape
One assignee leads the field with 14 of the 64 records in scope, well ahead of the rest of the top five, which each hold closer to 4 records. Together the top five assignees account for 62.5% of all records, and the top ten reach 93.8%, so filing rights in this narrow area are concentrated among a small group of universities and biotech firms. A newcomer should expect to negotiate around this cluster's existing claims rather than find open ground at the very top of the ranking.
Filings grew from 1 in 2021 to 3 in 2024, a +200% increase over that three-year span, after an earlier peak of 5 filings in 2019. The apparent drop in 2025 and 2026 is a publication-lag artefact — patent publication typically trails filing by around 18 months, so the most recent one to two years are always undercounted. Based on the last fully complete years, the honest read is growth, not decline.
Biological method claims dominate: C12N classifications appear in 90.6% of the 64 records. Apparatus and monitoring classes are comparatively thin — C12M bioreactor and apparatus claims reach 32.8% and C12Q enzyme/DNA measurement claims only 9.4%. That gap suggests real-time sensing and closed-loop control hardware for lactate, ammonia, pH or redox state is less densely claimed than the underlying cell-culture biology, which is where a first-mover apparatus claim would have more room.
EP2825638A1, filed by National University of Singapore and published 2015-01-21, claims methods of generating functional human brown adipocytes by exposing stem cells, progenitor cells or white adipocytes to a differentiation cocktail containing browning agents such as macromolecular crowders. It also covers the resulting adipocyte populations, their downstream uses, and administering a pharmaceutical composition built from that cocktail to an individual. Anyone working on brown-fat differentiation protocols using crowding or browning-agent cocktails should check this filing's exact claim scope before designing a similar protocol.
The United States receives the most filings at 19, followed by the European Patent Office at 16 and the WIPO PCT route at 8. Australia, Israel and Canada each see single-digit counts, in the 3-4 range. This distribution suggests the US and Europe are the primary commercial battlegrounds for metabolite-control claims in stem cell culture, with PCT filings used to keep international options open before national-phase decisions.
Research Stem Cell Culture Metabolite Control in depth with Eureka
Go past this page: query the whole stem cell culture metabolite control corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.